Analysts Issue Forecasts for PACB FY2025 Earnings

Pacific Biosciences of California, Inc. (NASDAQ:PACB) – Research analysts at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for shares of Pacific Biosciences of California in a research report issued to clients and investors on Tuesday, February 18th. Cantor Fitzgerald analyst R. Osborn now expects that the biotechnology company will post earnings per share of ($0.68) for the year, down from their prior estimate of ($0.62). The consensus estimate for Pacific Biosciences of California’s current full-year earnings is ($0.71) per share.

Other equities analysts also recently issued reports about the company. Stephens reissued an “overweight” rating and set a $2.50 target price on shares of Pacific Biosciences of California in a research note on Friday, February 14th. StockNews.com raised Pacific Biosciences of California to a “sell” rating in a research note on Friday, February 14th. UBS Group downgraded Pacific Biosciences of California from a “buy” rating to a “neutral” rating and set a $2.00 price objective for the company. in a research note on Monday, November 11th. The Goldman Sachs Group dropped their price objective on Pacific Biosciences of California from $1.75 to $1.50 and set a “neutral” rating for the company in a research note on Tuesday. Finally, Scotiabank dropped their price objective on Pacific Biosciences of California from $7.00 to $6.00 and set a “sector outperform” rating for the company in a research note on Monday, November 11th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $2.83.

Pacific Biosciences of California Price Performance

Shares of PACB stock opened at $1.77 on Thursday. The stock has a 50 day simple moving average of $1.78 and a 200-day simple moving average of $1.79. Pacific Biosciences of California has a 12-month low of $1.16 and a 12-month high of $6.09. The company has a debt-to-equity ratio of 1.97, a current ratio of 9.74 and a quick ratio of 8.64.

Pacific Biosciences of California (NASDAQ:PACB) last issued its earnings results on Thursday, February 13th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.20). The business had revenue of $39.22 million during the quarter, compared to the consensus estimate of $39.20 million. Pacific Biosciences of California had a negative return on equity of 42.89% and a negative net margin of 200.40%. During the same period in the prior year, the business posted ($0.27) EPS.

Institutional Investors Weigh In On Pacific Biosciences of California

Hedge funds have recently made changes to their positions in the business. FMR LLC grew its stake in shares of Pacific Biosciences of California by 641.3% during the 3rd quarter. FMR LLC now owns 408,151 shares of the biotechnology company’s stock valued at $694,000 after buying an additional 353,092 shares during the period. State Street Corp boosted its holdings in Pacific Biosciences of California by 5.7% in the third quarter. State Street Corp now owns 6,276,156 shares of the biotechnology company’s stock valued at $10,669,000 after acquiring an additional 340,766 shares during the last quarter. Soros Fund Management LLC grew its position in Pacific Biosciences of California by 23.6% during the third quarter. Soros Fund Management LLC now owns 2,098,000 shares of the biotechnology company’s stock valued at $3,567,000 after acquiring an additional 400,000 shares during the period. Barclays PLC increased its stake in Pacific Biosciences of California by 143.0% during the third quarter. Barclays PLC now owns 595,150 shares of the biotechnology company’s stock worth $1,011,000 after acquiring an additional 350,196 shares during the last quarter. Finally, Senvest Management LLC raised its holdings in shares of Pacific Biosciences of California by 36.1% in the 3rd quarter. Senvest Management LLC now owns 1,093,954 shares of the biotechnology company’s stock worth $1,860,000 after purchasing an additional 290,000 shares during the period.

Insiders Place Their Bets

In other news, insider Michele Farmer sold 24,349 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $1.88, for a total transaction of $45,776.12. Following the sale, the insider now owns 187,592 shares in the company, valued at $352,672.96. This trade represents a 11.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Oene Mark Van sold 34,405 shares of the firm’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $2.03, for a total value of $69,842.15. Following the sale, the insider now owns 1,597,454 shares in the company, valued at $3,242,831.62. This trade represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. 2.40% of the stock is currently owned by company insiders.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.